▌解決的核心問題
胸腔引流管是開心手術後不可或缺的術後照護裝置，負責引流胸腔積血、並提供醫師即時監測病人恢復狀況的依據。然而，臨床文獻顯示，術後胸管阻塞率高達 36%（Boyle EM Jr, 2015）。一旦阻塞，兩大核心功能同時失效：
引流失效：血液無法排出，積壓於胸腔，危及心肺功能
監測失效：醫師無法判斷引流量減少是病人好轉，還是管路堵塞，誤判率達 50%（Akira Shiose, 2010）
再開刀成本超過 6 萬美元/次，台灣每年約 400 例需再手術，累計系統損耗達 2,400 萬美元；美國已有醫院因延誤治療付出高達 600 萬美元賠償金。
現行主要競品（PleuraFlow、Thoraguard）各有結構性缺陷：前者無監測功能、高度人力依賴；後者閥門必須保持乾燥，一旦潮濕進入水氣即失效阻塞，且主機重達數公斤，成本結構不適合短期置管市場，美國市佔率僅 0.5%。
▌產品：AnXin 安心引流系統
AnXin Drainage System 是一套整合主動預防、智慧警示與標準化術後照護的胸腔引流解決方案，重量僅 500 克，輕鬆融入現行臨床流程，無需改變護理作業習慣。
AnXin 擁有三大核心技術模組：
① 螺旋清除導管
採雙軸旋轉清除機制，物理破壞血塊與纖維蛋白附著，同時進行自動清除，減少人工介入。操作壓力嚴格控制在 < -30 cmH₂O，確保安全不傷組織。
② 攜帶式恆壓幫浦
提供穩定負壓（-20 至 -30 cmH₂O），支援病人從 ICU 移動至一般病房甚至走廊，讓術後早期下床活動成為可能，加速復原進程。
③ 智慧韌體
內建壓力感測模組，即時判斷清除效果；依阻塞程度自動調節清除強度；清除失敗時即時發出警報，讓護理師在 5 分鐘內識別阻塞，取代過去 37 分鐘的手動疏通。
▌初步驗證數據
實驗室測試結果顯示，AnXin 相較於傳統引流系統：
引流效率提升 3 倍（AnXin：157 ml/min vs. 傳統：50 ml/min）
管路殘留降低 10 倍（AnXin：0.05 g vs. 傳統：0.5 g）
▌商業模式
採「主機 + 耗材」訂閱式商業模式：
主機 0 元導入，繞過醫院採購審核流程，加速進入臨床試點
耗材患者自費，調查顯示患者付費意願達 64.2%，耗材為主要獲利來源
此模式降低醫院採購門檻，同時確保可持續的耗材收入流。

PlexBio is developing a closed, fully automated molecular diagnostic platform intended to identify sepsis-associated pathogens and antimicrobial-resistance (AMR) markers directly from whole blood. The system integrates culture-free sample preparation, highly multiplexed PCR, πCode™ precision image-coded magnetic microdisc hybridization, automated signal decoding, and result interpretation in a single sample-to-result workflow.

Its key innovation is the combination of direct-from-blood access, broad multiplex detection, and automation designed for the early sepsis treatment window, before conventional blood-culture results become available. Preliminary feasibility studies have demonstrated detection of selected pathogens in spiked whole-blood samples at low organism concentrations and successful integration of PCR and πCode™ hybridization modules.

The platform is designed to complement, rather than replace, existing sepsis workflows by providing earlier pathogen and AMR information to support antimicrobial decision-making. Compared with culture-dependent molecular panels, the proposed system offers earlier intervention potential, clinically relevant breadth, scalable panel expansion, and a deployable cartridge-based business model. The same platform architecture may subsequently be extended to pneumonia, meningitis, and other acute infectious diseases.

GelAtlas 是一套水膠式三維組織培養平台，設計用於提升類器官、腫瘤球體與病人來源腫瘤組織模型的培養穩定性、影像分析品質與實驗再現性。透過可調控的水膠微孔陣列，GelAtlas 可將三維組織固定於明確位置，支援長時間培養、高解析影像追蹤、藥物反應測試與完整組織回收。此平台可由單晶片驗證擴展至多腔室格式，適用於學研單位、CRO 與藥廠研發流程，作為研究用三維組織模型與藥物篩選平台。

Our patented, redox-responsive Cell Sheet Engineering (CSE) platform delivers a paradigm-shifting treatment for osteoarthritis, addressing a massive global unmet clinical need. By replacing conventional thermo-responsive systems with a smart substrate grafted with poly(gamma-glutamic acid) and disulfide linkers, our technology achieves a biomimetic hydrated stiffness of 16.2 MPa. This perfectly mirrors native human cartilage, providing the essential mechanical cues to suppress chondrocyte dedifferentiation. Utilizing a mild reducing agent, the platform enables the non-enzymatic harvesting of intact cell sheets with a fully preserved extracellular matrix (ECM). This scaffold-free approach eliminates foreign-body reactions and physical tissue integration barriers. The preserved endogenous ECM acts as a natural biological adhesive, driving seamless graft integration and the robust regeneration of high-quality, Collagen II-rich hyaline cartilage in vivo. Commercially, this chemically specific detachment ensures highly uniform, GMP-compatible manufacturing scalability. Backed by US patent US9,546,349 B2, our highly reproducible platform is uniquely positioned to capture the regenerative medicine market, offering a scalable, clinically superior, and commercially viable therapeutic strategy for functional articular cartilage repair.

本技術針對全球臨床骨缺損修復的龐大需求，推出一款源自人工養殖、具備耐熱特性的鹿角珊瑚高性能仿生骨移植物。我們有效善用豐富且可再生的海洋資源，透過專利的熱燒結製程去除有機物質以確保臨床安全性，並完美模擬人類骨結構並維持優異的物理強度。 本材料具備極佳的生物相容性，離體細胞實驗證實其完全無細胞毒性，且能顯著加速骨母細胞的貼附與增殖，同時大幅上調核心造骨標記基因（ALP、OCN、Runx2、osterix）的誘導表現。長達 5 個月的大鼠顱骨臨界大小缺損活體模型更證實，本製備材料具備與新生骨生長同步的同步降解率，其新生骨體積、骨質密度與再生總骨質量均顯著提升。 本技術擺脫了傳統野生珊瑚採集所面臨的生態破壞、變異性高與 CITES 國際法規禁令，透過高度品質可控、規模化的人工養殖平台，能為全球每年超過 50 億美金的骨科與牙科骨材市場，提供穩定、安全且具高度臨床價值的工業化供應鏈解方。目前核心技術已成功發表於國際期刊 Materials & Design 並取得台灣發明專利，具備極高的商業轉譯可行性與 B2B 技術授權潛力。

Fluidiconic Biotechnology is building the functional oncology decision infrastructure for next-generation cancer drug development. Our MedSelect® platform integrates human-relevant tumor-on-a-chip models, intelligent automation, and functional oncology databases to accelerate drug discovery, optimize therapeutic strategies, and improve translational success.